Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MCRB vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MESO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

MESO Overall Winner 6-Pillar Tally: MCRB 1 – 4 MESO (1 Tie) Matrix Metrics: MCRB 4 – 6 MESO

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Seres Therapeutics, Inc. (MCRB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MCRB carries a Unified Composite Score of 50.6/100 (HOLD) at $1.42 (10.8x Forward P/E, -3115.1% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Composite vs. Pillar Nuance: While MCRB currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. MESO 35.5/100 SELL), MESO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -3115.1% operating margin) and revenue trajectory (+390.7% vs. +68.9% YoY).
  • Technical & Structure Timing Caution: MCRB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MCRB vs MESO
MCRB NASDAQ
Seres Therapeutics, Inc.
Pharmaceutical Preparations
$1.42
+1.43% 1D
Market Cap $13.9M
TTM Revenue $2.1M
Forward P/E 10.8x
Beta / 30D Vol 0.64β · 97% Vol
Unified Composite Score
50.6 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 66.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.6%), weak momentum, RSI 24
RSI-14: 23.9 · SMA20: $1.85 · SMA50: $2.87
MESO NASDAQ Head-to-Head Winner
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (MCRB 1 – 4 MESO)

Columns: Metric · MCRB · MESO
1. Valuation Multiples MCRB
Forward P/E 10.8x N/M
Trailing P/E 10.8x N/M
PEG Ratio N/M N/M
EV / Revenue 15.1x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +68.9% +390.7%
Earnings Growth (YoY) -91.9% +0.0%
TTM Revenue (USD) $2.1M $120M
Market Cap $13.9M $1.7B
3. Profitability & Quality MESO
Gross Margin N/A 80.0%
Operating Margin -3115.1% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) -144.3% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$63M EBITDA -$45M EBITDA
Cash Flow Margin N/A -37.1% EBITDA Mgn
Net Cash / Leverage $18M Net Debt (1.67x D/E) $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MESO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 95.5% (22nd %ile) 76.8% (37th %ile)
Put/Call OI Skew 104.33x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MCRB (4) vs MESO (6)
Institutional Metric MCRB MESO Criterion Row Edge
Market Capitalization
Scale
$13.9M $1.7B Larger Scale MESO
Trailing P/E Ratio
Valuation
10.8x N/M Lower Multiple MCRB
Forward P/E Ratio
Valuation
10.8x N/M Lower Multiple MCRB
Revenue Growth (YoY)
Growth
+68.9% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
-3115.1% -42.6% Higher Margin MESO
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin MCRB
Return on Equity (ROE)
Capital Efficiency
-144.3% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
0% ($1–$30) 6% ($12–$22) Stronger Trend MESO
Beta / 30D Volatility
Risk Regime
0.64β · 97% Vol 1.18β · 78% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
50.6 / 100 (HOLD) 35.5 / 100 (SELL) Higher Composite MCRB
Trailing 12M Revenue (USD)
Operating Scale
$2.1M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 15.1x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$63M EBITDA ($18M Net Debt (1.67x D/E)) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MESO +36.18 pp
MCRB: -42.28% · MESO: -6.1%
3M Horizon MESO +42.09 pp
MCRB: -67.28% · MESO: -25.19%
6M Horizon MESO +66.47 pp
MCRB: -81.29% · MESO: -14.82%
1Y Horizon MESO +75.11 pp
MCRB: -91.53% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MCRB vs MESO. Trailing 12-month operating profitability (MCRB -3115.1% vs MESO -42.6%) and valuation multiples (MCRB 10.8x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MCRB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.1M
Gross MarginN/A
Op. Margin-3115.1%
ROE / Fwd P/E-144.3% · 10.8x
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MCRB BREAKDOWN
93d in phase · OBV DISTRIBUTION
Current IV 95.5%
IV Percentile 22nd %ile
Put/Call OI Skew 104.33x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MCRB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MCRB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $13.9M market capitalization and -3115.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MCRB vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Seres Therapeutics, Inc. (MCRB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MCRB carries a Unified Composite Score of 50.6/100 (HOLD) at $1.42 (10.8x Forward P/E, -3115.1% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Composite vs. Pillar Nuance: While MCRB currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. MESO 35.5/100 SELL), MESO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -3115.1% operating margin) and revenue trajectory (+390.7% vs. +68.9% YoY). Technical & Structure Timing Caution: MCRB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MCRB posts +68.9% YoY revenue growth and -91.9% YoY earnings growth on $2.1M TTM revenue (N/A gross margin, -3115.1% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, MCRB generates $2.1M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, MCRB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

MCRB screens cheaper on headline valuation multiples. MCRB trades at 10.8x Forward P/E, 10.8x Trailing P/E, N/M PEG, and 15.1x EV/Revenue (unreported EBITDA margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MCRB (-144.3% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MCRB carries 95.5% implied volatility (22nd %ile, Compressed (<25th %ile)), a 104.33x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.64β · 97% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.